AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
166.04-1.41 (-0.84%)
At close: 4:00PM EDT

166.42 0.38 (0.23%)
After hours: 4:15PM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close167.45
Bid165.44 x 100
Ask167.29 x 100
Day's Range165.57 - 167.98
52 Week Range133.64 - 184.21
Avg. Volume3,942,191
Market Cap122.28B
PE Ratio (TTM)16.21
Earnings DateN/A
Dividend & Yield4.60 (2.76%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire21 minutes ago

    European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

    THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. The EC also approved AMGEVITA for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn's disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).

  • Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
    Investor's Business Daily2 hours ago

    Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can

    Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.

  • How This Company Is Taking on Amgen
    Motley Fool7 hours ago

    How This Company Is Taking on Amgen

    The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.